Sign In
Buy JNJ
$241.00
+1.92 (+0.80%)
At Close: Jun 24, 2026
Icotrokinra (JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, met its co-primary endpoints in patients with moderate to severe plaque psori
Johnson & Johnson (JNJ) Management presents at Stifel 2024 Healthcare Conference (Transcript)
04:02pm, Monday, 18'th Nov 2024
Johnson & Johnson (NYSE:JNJ ) Stifel 2024 Healthcare Conference November 18, 2024 10:55 AM ET Company Participants Michael Bodner - Group President, Heart Recovery and Circulatory Restoration Conferen
CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
08:45am, Monday, 18'th Nov 2024
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
As Drug Maker Stocks Fall, Pressure Builds On PhRMA To Derail RFK, Jr.
10:03pm, Friday, 15'th Nov 2024
Stocks of major drug makers and biotech companies tumbled in trading late this week after President-elect Donald Trump announced that he wants vaccine skeptic Robert F. Kennedy Jr. to lead the U.S. De
Johnson & Johnson (JNJ) Guggenheim Global Healthcare Conference (Transcript)
02:15pm, Friday, 15'th Nov 2024
Johnson & Johnson (NYSE:JNJ ) Guggenheim Global Healthcare Conference November 12, 2024 10:30 AM ET Company Participants Biljana Naumovic - Worldwide VP, Global Commercial Strategy, Oncology Mark Wild
Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
09:40am, Friday, 15'th Nov 2024
Eli Lilly (LLY) became the second drugmaker in recent days to sue the U.S. government for rejecting their proposed changes to a program that requires selling discounted drugs to certain medical facili
2 Of The Cheapest, High-Quality Dividend Stocks On The Market
07:30am, Friday, 15'th Nov 2024
In today's market, sticky inflation and elevated valuations make stock picking a challenge. But some dividend stocks still stand out as strong, long-term picks. These two dividend stocks offer growth
Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
12:35pm, Thursday, 14'th Nov 2024
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
10:00am, Thursday, 14'th Nov 2024
Adults with moderately-to-severely active Sjögren's disease who received investigational FcRn blocker nipocalimab had improvements in disease activity scores at 24 weeks with accompanying significant
Johnson & Johnson: Tracking Well Above The Industry
09:10am, Wednesday, 13'th Nov 2024
In the second half of 2024, Johnson & Johnson made significant progress in developing its oncology franchise. So, Darzalex sales were $3.02 billion in the third quarter of 2024, up 20.7% year-on-year,
The Breakthrough Therapy Designation (BTD) for investigational nipocalimab in Sjögren's disease, a prevalent autoantibody disease with no approved advanced therapies, is supported by results from the
Johnson & Johnson Enters Oversold Territory
12:05pm, Monday, 11'th Nov 2024
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec
5 Relatively Secure And Cheap Dividend Stocks - November 2024: Yields Up To 9%
09:00am, Saturday, 09'th Nov 2024
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering large discounts to their historical norms. We go over our filtering pr
If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before th
If approved, DARZALEX FASPRO ® will become the first treatment option for patients with smoldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat b
